Northwest Biotherapeutics (NWBO) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to 3.55.
- Northwest Biotherapeutics' Equity Ratio fell 2990.52% to 3.55 in Q3 2025 from the same period last year, while for Sep 2025 it was 3.55, marking a year-over-year decrease of 2990.52%. This contributed to the annual value of 3.54 for FY2024, which is 4976.73% down from last year.
- Northwest Biotherapeutics' Equity Ratio amounted to 3.55 in Q3 2025, which was down 2990.52% from 3.4 recorded in Q2 2025.
- In the past 5 years, Northwest Biotherapeutics' Equity Ratio ranged from a high of 1.7 in Q1 2023 and a low of 42.73 during Q3 2023
- In the last 5 years, Northwest Biotherapeutics' Equity Ratio had a median value of 3.5 in 2022 and averaged 6.46.
- In the last 5 years, Northwest Biotherapeutics' Equity Ratio plummeted by 112086.1% in 2023 and then skyrocketed by 9360.58% in 2024.
- Over the past 5 years, Northwest Biotherapeutics' Equity Ratio (Quarter) stood at 3.09 in 2021, then tumbled by 32.46% to 4.09 in 2022, then soared by 42.28% to 2.36 in 2023, then plummeted by 49.77% to 3.54 in 2024, then decreased by 0.41% to 3.55 in 2025.
- Its Equity Ratio was 3.55 in Q3 2025, compared to 3.4 in Q2 2025 and 3.62 in Q1 2025.